Takeda has announced that the National Institute for Health and Care Excellence (NICE) has recommended Ninlaro with lenalidomide and dexamethasone.
The National Institute for Health and Care Excellence (NICE) has recommended Ninlaro® (ixazomib) with lenalidomide and dexamethasone for treating relapsed/refractory multiple myeloma (RRMM).
Lund Sweden, February 7, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study of tasquinimod in relapsed or refractory multiple myeloma. In this part of the study treatment with tasquinimod will be tested together with the orally administered antimyeloma agents ixazomib, lenalidomide, and dexamethasone (IRd).
Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) (“Takeda”) today announced the results of the Phase 3 TOURMALINE-MM2 trial that highlights the addition of NINLARO ™ (ixazomib) to lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo in newly diagnosed multiple myeloma patients who are not eligible for autologous stem cell transplantation. These data will be presented at the Society of Hematologic Oncology (SOHO) virtual science meeting on Wednesday, September 9, 2020 at 6:15 PM. CT.
A Phase 3 clinical trial, TOURMALINE-MM2, evaluating Takeda Pharmaceutical Company Limited's (NYSE:TAK) Ninlaro (ixazomib), added to lenalidomide (sold as Revlimid by Celgene) and dexamethasone (l+d), in newly diagnosed (first-line) multiple myeloma (MM) patients ineligible for autologous stem cell transplant failed to achieve the primary endpoint. The results were virtually presented at the Society of Hematologic Oncology Annual Meeting.
MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis
Cambridge, Mass. and Osaka, JAPAN, June 12, 2020 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced it will orally present the results of two studies at the 25th Congress of the European Hematology Association (EHA). Presentations are available online starting Friday, June 12, 2020, and include positive results from TOURMALINE-MM4, a Phase 3, randomized clinical trial evaluating the effect of single-agent oral NINLARO™ (ixazomib) as a first-line maintenance therapy in adult patients diagnosed with multiple myeloma who had not been treated with stem cell transplantation. Takeda is also presenting key insights from the US MM-6 trial, which investigates the effectiveness and safety of an in-class transition to oral NINLARO in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who have previously received a parenteral bortezomib-based triplet induction therapy.
Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed transplant ineligible multiple myeloma, revealing that the therapy, when combined with lenalidomide and dexamethasone, unfortunately did not meet its primary endpoint.
Takeda’s ongoing bid to expand the audience for its cancer drug Ninlaro has suffered some setbacks this year, but now the company can claim one big win—and investors are cheering.
Five months after dismal trial results convinced Takeda to scrap an entire Phase III program for their multiple myeloma drug Ninlaro, the Japanese giant announced a different late-stage trial has met its primary endpoint — although they have yet to release any data.